

August 26, 2026

Alexion Notice Regarding Refunds to 340B Covered Entities

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, PLC (“Alexion”), has recalculated the 340B Ceiling Prices for the products and corresponding national drug codes (“NDC”) referenced below for the sales period of July 1, 2025, through June 30, 2026 (“Sales Period”). As a result of the recalculated 340B Ceiling Price, Alexion has determined a refund may be owed to 340B Covered Entities that purchased the below products during the Sales Period. Alexion is not seeking reimbursement or repayment where Covered Entities paid a lower price than the recalculated 340B ceiling price for the indicated period, and any such amounts will not be used as offsets in determining the aggregate amount of any refund due.

The table below identifies the NDC, Product, and Sales Period that are subject to a refund. The recalculated Ceiling Prices are the result of revised pricing data submitted to the Centers for Medicare & Medicaid Services.

NDC 11	Product Description	340B Sales Period
25682-0028-01	Ultomiris 1100mg/11mL	3Q25, 4Q25,1Q26,2Q26
25682-0025-01	Ultomiris 300mg/3ml	3Q25, 4Q25,1Q26,2Q26
25682-0001-01	Soliris 300mg/30ml	3Q25, 4Q25,1Q26,2Q26
25682-0010-12	Strensiq 18mg/0.45ml vial, 12ct	1Q26
25682-0013-12	Strensiq 28mg/0.7ml vial, 12ct	1Q26
25682-0016-12	Strensiq 40mg/1ml vial, 12ct	1Q26
25682-0019-12	Strensiq 80mg/0.8ml vial, 12ct	1Q26

Alexion has determined the credit amounts owed to each affected 340B Covered Entity and has coordinated with its wholesalers to issue applicable refunds. Alexion has processed refunds as credits to each Covered Entity’s validated wholesaler account.

If a Covered Entity believes it is entitled to a refund and has not received credit through its wholesaler account by September 15, 2026, the Covered Entity should contact Alexion at 340bnotice@alexion.com to request a review and processing of any applicable refund. Please include “340B Refund-2026” in the subject line and include the applicable 340B ID, Entity Name, Address, NDC, Product Description, Quantity Purchased, Wholesaler and Invoice Date.

Alexion has asked the Health Resources and Services Administration (HRSA) to post this Notice on HRSA’s public website to ensure transparency to 340B Covered Entities. Please direct any questions and/or requests for additional information to Alexion at the following email address: 340bnotice@alexion.com.